Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

NOT YET RECRUITING

NCT07271875

PHASE3

Neuromuscular Blocking Agents on Gastrointestinal Function Following Colorectal Surgery

Sponsor: Xijing Hospital

View on ClinicalTrials.gov

Summary

This study is a clinical research project conducted at Xijing Hospital to compare the effects of two different neuromuscular blockade reversal strategies on the recovery of gastrointestinal (GI) function after colorectal surgery. Many patients experience slow recovery of bowel function after colorectal surgery, which can lead to discomfort, nausea, vomiting, and a longer hospital stay. This study investigates whether using one medication (sugammadex) to reverse muscle relaxants used during anesthesia leads to better and faster recovery of gastrointestinal function compared to a traditional combination of medications (neostigmine with atropine). The study will include 560 adults scheduled for elective colorectal surgery. Participants will be randomly assigned to one of two groups to receive either: Sugammadex (2 mg/kg), OR Neostigmine (30 μg/kg) + Atropine (15 μg/kg) The assigned study drug will be given by intravenous injection at the end of surgery, once measurements show the muscle relaxant is starting to wear off. The patients, surgeons, outcome assessors, and statisticians will be blinded. The main goal is to see if more patients in one group recover their gastrointestinal function within 72 hours after surgery. Gastrointestinal recovery is strictly defined as both being able to tolerate food/drinks without significant nausea/vomiting AND having passed gas or had a bowel movement. The study will also compare many other important outcomes between the groups, including: 1. Time to first passage of gas, first bowel movement, and first toleration of food. 2. Pain scores and opioid pain medication use. 3. Rates of nausea and vomiting. 4. Overall quality of recovery and patient satisfaction. 5. Length of hospital stay and total hospitalization costs. 6. Occurrence of complications within 30 days after surgery. 7. The safety of both reversal strategies will be closely monitored throughout the study by recording any adverse events. This research aims to provide high-quality evidence to help anesthesiologists and surgeons choose the best method to reverse muscle relaxation, potentially leading to faster recovery, fewer complications, and a better overall experience for patients undergoing colorectal surgery.

Official title: Effect of Neuromuscular Reversal With Neostigmine/Atropine Versus Sugammadex on Postoperative Gastrointestinal Function Recovery Following Colorectal Surgery

Key Details

Gender

All

Age Range

18 Years - 100 Years

Study Type

INTERVENTIONAL

Enrollment

560

Start Date

2026-01-01

Completion Date

2027-12-31

Last Updated

2025-12-09

Healthy Volunteers

Conditions

Postoperative Gastrointestinal Dysfunction (POGD)Postoperative Ileus Colorectal Surgery

Interventions

DRUG

Neostigmine + Atropine

Participants received Neostigmine 30 μg/kg + Atropine 15 μg/kg after surgery once a train-of-four ratio of 0.9 and sufficient spontaneous breathing were confirmed.

DRUG

Sugammadex

Participants received sugammadex 2 mg/kg after surgery once a train-of-four ratio of 0.9 and sufficient spontaneous breathing were confirmed.

Inclusion Criteria: * Age ≥ 18 years * American Society of Anesthesiologists (ASA) physical status classification I-III * Preoperative Mini-Mental State Examination (MMSE) score \> 23 * Patients scheduled for elective colorectal surgery under general anesthesia. Disease diagnoses include colorectal cancer, benign polyps, benign strictures, or diverticular disease. * Provide informed consent Exclusion Criteria: * Presence of psychiatric disorders, cognitive impairment, or language communication barriers that may affect assessment compliance. * Body Mass Index (BMI) ≥ 35 kg/m². * Severe hepatic dysfunction (Child-Pugh Class C) or renal dysfunction (estimated glomerular filtration rate \< 30 ml/min/1.73m² and/or receiving renal replacement therapy). * Pre-existing severe gastrointestinal dysfunction (e.g., intestinal obstruction, active inflammatory bowel disease, severe constipation/diarrhea); receipt of neoadjuvant therapy preoperatively; planned stoma creation surgery; or scheduled for low rectal surgery (e.g., low anterior resection, abdominoperineal resection). * History of neuromuscular disorders (e.g., myasthenia gravis) or malignant hyperthermia. * History of opioid abuse, or chronic non-surgical pain requiring long-term analgesic therapy. * Anticipated difficult airway, or patients planned for postoperative transfer to the intensive care unit (ICU) while intubated. * Contraindications to the use of neostigmine, atropine, sugammadex, or rocuronium (e.g., known drug allergy, epilepsy, unstable angina, asthma, glaucoma, uncontrolled malignant arrhythmias especially atrioventricular block, severe cardiac valve stenosis); or current use of medications that may significantly influence the effects of neuromuscular blocking agents (e.g., antibiotics such as tetracyclines, aminoglycosides, polymyxins, and clindamycin; antiepileptic drugs; lithium; certain antidepressants such as sertraline and amitriptyline). * Pregnant or lactating women. * Current participation in other clinical trials that may interfere with the results of this study.

Clinical Research Directory

Neuromuscular Blocking Agents on Gastrointestinal Function Following Colorectal Surgery

Summary

Key Details

Conditions

Interventions

Eligibility Criteria